Cairn Diagnostics Approved for At-Home Admin of Breath Test
Cairn Diagnostics has announced that the U.S. FDA has expanded the approval of the company’s 13C-Spirulina GEBT to now include “at home” administration.
Read MorePosted by Chris Wolski | Sep 16, 2021 | Disease States |
Cairn Diagnostics has announced that the U.S. FDA has expanded the approval of the company’s 13C-Spirulina GEBT to now include “at home” administration.
Read MorePosted by Toni Mitchell | Sep 13, 2021 | Diabetes & Metabolic Diseases |
Low-cost screen printed carbon sensors — used to rapidly detect bacteria commonly found in wounds — could pave the way for a real-time medical device.
Read MorePosted by Chris Wolski | Sep 3, 2021 | Diabetes & Metabolic Diseases |
People with type 2 diabetes should be considered in remission after sustaining normal blood sugar levels for three months or more.
Read MorePosted by Chris Wolski | Aug 30, 2021 | Diabetes & Metabolic Diseases |
Testing for, monitoring, and controlling diabetes continues to become more robust, cost-effective, and nuanced.
Read MorePosted by Chris Wolski | Aug 24, 2021 | Unknown Origin & Other Cancer Types |
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read More